1,686 Shares in Thermo Fisher Scientific Inc. (NYSE:TMO) Purchased by Meritage Portfolio Management

Meritage Portfolio Management bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,686 shares of the medical research company’s stock, valued at approximately $895,000.

A number of other large investors have also added to or reduced their stakes in TMO. Raleigh Capital Management Inc. grew its position in Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. Cedar Mountain Advisors LLC boosted its stake in Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after buying an additional 46 shares in the last quarter. Financial Connections Group Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $53,000. Operose Advisors LLC lifted its position in Thermo Fisher Scientific by 250.0% in the third quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 75 shares during the last quarter. Finally, Valley National Advisers Inc. lifted its position in Thermo Fisher Scientific by 40.5% in the third quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 32 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Raymond James upped their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Barclays upped their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday. Royal Bank of Canada upped their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Thermo Fisher Scientific Price Performance

TMO traded up $1.86 during trading on Friday, hitting $573.59. 804,480 shares of the company traded hands, compared to its average volume of 1,553,806. The company has a market cap of $218.95 billion, a PE ratio of 36.70, a P/E/G ratio of 2.44 and a beta of 0.80. The stock’s 50-day simple moving average is $573.08 and its two-hundred day simple moving average is $529.36. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a current ratio of 1.70, a quick ratio of 1.39 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. Insiders have sold 50,277 shares of company stock valued at $28,513,384 in the last ninety days. Insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.